Overview
Norelgestromin is a drug used in contraception. Norelgestromin is the active progestin responsible for the progestational activity that occurs in women after application of ORTHO EVRA patch.
Indication
Norelgestromin is used for contraception and menopausal hormonal therapy. Norelgestromin may potentially be used in breast cancer treatment due to its inhibitory effect on estrone sulfatase . They convert sulfated steroid precursors to estrogen during pregnancy.
Associated Conditions
- Polycystic Ovarian Syndrome (PCOS)
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2019/07/12 | Phase 1 | Completed | |||
2017/09/06 | Phase 4 | Completed | |||
2007/02/26 | Phase 2 | UNKNOWN | |||
2005/12/05 | Phase 4 | Completed | Janssen Pharmaceutica N.V., Belgium | ||
2005/11/24 | Phase 1 | Completed | |||
2005/11/24 | Phase 1 | Completed | |||
2005/11/17 | Phase 1 | Completed | |||
2005/10/12 | Phase 3 | Completed | |||
2005/10/12 | Phase 3 | Completed | |||
2005/10/12 | Phase 3 | Completed |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| Bryant Ranch Prepack | 72162-2220 | TRANSDERMAL | 150 ug in 1 d | 1/5/2024 | |
| Zydus Pharmaceuticals USA Inc. | 70710-1190 | TRANSDERMAL | 150 ug in 1 mg | 9/16/2023 | |
| Zydus Lifesciences Limited | 70771-1777 | TRANSDERMAL | 150 ug in 1 mg | 9/16/2023 | |
| Mylan Pharmaceuticals Inc. | 0378-3340 | TRANSDERMAL | 150 ug in 1 d | 2/4/2021 | |
| Amneal Pharmaceuticals NY LLC | 69238-1521 | TRANSDERMAL | 150 ug in 1 d | 12/30/2023 | |
| AvKARE | 42291-930 | TRANSDERMAL | 150 ug in 1 d | 5/15/2023 | |
| Amneal Pharmaceuticals LLC | 65162-358 | TRANSDERMAL | 150 ug in 1 d | 5/1/2023 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
Authorised | 8/22/2002 |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| EVRA TRANSDERMAL PATCH (6 mg/600 mcg) | SIN12423P | PATCH | 6 mg/patch | 9/17/2003 |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
|---|---|---|---|---|---|
| EVRA -(6/0.75) | 02246340 | Patch (Extended Release) - Transdermal | 6 MG | 10/24/2002 | |
| EVRA | searchlight pharma inc | 02248297 | Patch (Extended Release) - Transdermal | 200 MCG / 24 HOUR | 12/24/2003 |
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
|---|---|---|---|---|---|
| EVRA 203 MICROGRAMOS/24 HORAS + 33,9 MICROGRAMOS/24 HORAS PARCHE TRANSDERMICO | 02223001IP3 | PARCHE TRANSDÉRMICO | Medicamento Sujeto A Prescripción Médica | Commercialized | |
| EVRA 203 MICROGRAMOS/24 HORAS + 33,9 MICROGRAMOS/24 HORAS PARCHE TRANSDERMICO | 02223002IP4 | PARCHE TRANSDÉRMICO | Medicamento Sujeto A Prescripción Médica | Commercialized | |
| EVRA 203 MICROGRAMOS/24 HORAS + 33,9 MICROGRAMOS/24 HORAS PARCHE TRANSDERMICO | 02223002 | PARCHE TRANSDÉRMICO | Medicamento Sujeto A Prescripción Médica | Commercialized | |
| EVRA 203 MICROGRAMOS/24 HORAS + 33,9 MICROGRAMOS/24 HORAS PARCHE TRANSDERMICO | 02223002IP1 | PARCHE TRANSDÉRMICO | Medicamento Sujeto A Prescripción Médica | Commercialized | |
| EVRA 203 MICROGRAMOS/24 HORAS + 33,9 MICROGRAMOS/24 HORAS PARCHE TRANSDERMICO | 02223001 | PARCHE TRANSDÉRMICO | Medicamento Sujeto A Prescripción Médica | Commercialized | |
| EVRA 203 MICROGRAMOS/24 HORAS + 33,9 MICROGRAMOS/24 HORAS PARCHE TRANSDERMICO | 02223002IP2 | PARCHE TRANSDÉRMICO | Medicamento Sujeto A Prescripción Médica | Commercialized | |
| EVRA 203 MICROGRAMOS/24 HORAS + 33,9 MICROGRAMOS/24 HORAS PARCHE TRANSDERMICO | 02223001IP2 | PARCHE TRANSDÉRMICO | Medicamento Sujeto A Prescripción Médica | Commercialized | |
| EVRA 203 MICROGRAMOS/24 HORAS + 33,9 MICROGRAMOS/24 HORAS PARCHE TRANSDERMICO | 02223001IP4 | PARCHE TRANSDÉRMICO | Medicamento Sujeto A Prescripción Médica | Commercialized | |
| EVRA 203 MICROGRAMOS/24 hORAS + 33,9 MICROGRAMOS/24 HORAS PARCHE TRANSDERMICO | 02223001IP1 | PARCHE TRANSDÉRMICO | Medicamento Sujeto A Prescripción Médica | Commercialized | |
| EVRA 203 MICROGRAMOS/24 HORAS + 33,9 MICROGRAMOS/24 HORAS PARCHE TRANSDERMICO | 02223002IP3 | PARCHE TRANSDÉRMICO | Medicamento Sujeto A Prescripción Médica | Commercialized |
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Philippines FDA approvals found for this drug. | |||||
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Saudi SFDA approvals found for this drug. | |||||
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Malaysia NPRA approvals found for this drug. | |||||
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
|---|---|---|---|---|---|
| No UK EMC drug information found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.